Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:CRONNASDAQ:NAGENASDAQ:PRAXNASDAQ:YMAB On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCRONCronos Group$1.96+1.3%$1.87$1.60▼$2.58$753.50M1.061.31 million shs305,070 shsNAGENiagen Bioscience$11.90+1.0%$8.29$2.31▼$12.07$937.36M1.94844,405 shs121,581 shsPRAXPraxis Precision Medicines$42.55+3.3%$35.71$26.70▼$91.83$861.02M2.6384,338 shs48,165 shsYMABY-mAbs Therapeutics$5.06+3.8%$4.36$3.55▼$16.11$226.42M0.53306,395 shs15,492 shs7 Energy Stocks to Buy and Hold ForeverWith the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCRONCronos Group+0.52%-3.50%+4.89%-4.93%-23.41%NAGENiagen Bioscience+0.43%+11.13%+47.25%+37.78%+326.81%PRAXPraxis Precision Medicines+3.47%+14.13%+2.39%+8.85%-12.43%YMABY-mAbs Therapeutics+2.74%+10.43%+10.43%+0.41%-59.65%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationCRONCronos Group1.6385 of 5 stars0.05.00.00.03.30.01.3NAGENiagen Bioscience0.8869 of 5 stars2.50.00.00.03.10.00.0PRAXPraxis Precision Medicines2.8101 of 5 stars4.42.00.00.02.81.70.0YMABY-mAbs Therapeutics3.6633 of 5 stars4.42.00.00.02.44.20.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCRONCronos Group 0.00N/AN/AN/ANAGENiagen Bioscience 3.00Buy$13.009.24% UpsidePRAXPraxis Precision Medicines 2.80Moderate Buy$109.90158.31% UpsideYMABY-mAbs Therapeutics 2.82Moderate Buy$15.60208.61% UpsideCurrent Analyst Ratings BreakdownLatest YMAB, CRON, NAGE, and PRAX Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/2/2025PRAXPraxis Precision MedicinesOppenheimerSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageOutperform$97.005/29/2025YMABY-mAbs TherapeuticsOppenheimerSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOutperform ➝ Outperform$20.00 ➝ $15.005/28/2025YMABY-mAbs TherapeuticsWedbushSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform$21.00 ➝ $18.005/27/2025NAGENiagen BioscienceCanaccord Genuity GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$13.005/19/2025YMABY-mAbs TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$12.00 ➝ $11.005/14/2025YMABY-mAbs TherapeuticsTruist FinancialSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$18.00 ➝ $14.005/14/2025YMABY-mAbs TherapeuticsOppenheimerSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOutperform ➝ Outperform$21.00 ➝ $20.005/7/2025PRAXPraxis Precision MedicinesChardan CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$80.005/5/2025PRAXPraxis Precision MedicinesWedbushSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetUnderperform ➝ Underperform$26.00 ➝ $28.005/5/2025PRAXPraxis Precision MedicinesNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$80.00 ➝ $80.005/1/2025PRAXPraxis Precision MedicinesHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$105.00 ➝ $105.00(Data available from 6/4/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCRONCronos Group$124.59M6.05N/AN/A$2.87 per share0.68NAGENiagen Bioscience$107.93M8.69N/AN/AN/A∞PRAXPraxis Precision Medicines$8.12M106.70N/AN/A$7.92 per share5.37YMABY-mAbs Therapeutics$88.66M2.58N/AN/A$2.32 per share2.18Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCRONCronos Group-$73.96M$0.13N/A65.171.74-42.65%-2.56%-2.47%8/14/2025 (Estimated)NAGENiagen BioscienceN/A$0.1770.00∞N/AN/AN/AN/AN/APRAXPraxis Precision Medicines-$123.28M-$10.72N/AN/AN/A-9,409.22%-54.86%-50.52%8/12/2025 (Estimated)YMABY-mAbs Therapeutics-$21.43M-$0.64N/AN/AN/A-28.22%-24.61%-18.49%8/11/2025 (Estimated)Latest YMAB, CRON, NAGE, and PRAX EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/13/2025Q1 2025YMABY-mAbs Therapeutics-$0.22-$0.12+$0.10-$0.12$19.97 million$20.90 million5/8/2025Q1 2025CRONCronos Group$0.01$0.02+$0.01$0.02$45.44 million$33.62 million5/2/2025Q1 2025PRAXPraxis Precision Medicines-$3.20-$3.29-$0.09-$3.29$0.20 millionN/A3/4/2025Q4 2024YMABY-mAbs Therapeutics-$0.13-$0.15-$0.02-$0.15$26.70 million$26.50 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthCRONCronos GroupN/AN/AN/AN/AN/ANAGENiagen BioscienceN/AN/AN/AN/AN/APRAXPraxis Precision MedicinesN/AN/AN/AN/AN/AYMABY-mAbs TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCRONCronos GroupN/A24.2423.05NAGENiagen BioscienceN/AN/AN/APRAXPraxis Precision MedicinesN/A10.9610.96YMABY-mAbs TherapeuticsN/A3.923.54Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCRONCronos Group8.71%NAGENiagen Bioscience15.41%PRAXPraxis Precision Medicines67.84%YMABY-mAbs Therapeutics70.85%Insider OwnershipCompanyInsider OwnershipCRONCronos Group7.30%NAGENiagen Bioscience9.39%PRAXPraxis Precision Medicines2.70%YMABY-mAbs Therapeutics22.50%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCRONCronos Group450385.42 million356.14 millionOptionableNAGENiagen Bioscience12078.77 millionN/AN/APRAXPraxis Precision Medicines11020.37 million18.14 millionOptionableYMABY-mAbs Therapeutics15045.28 million34.71 millionOptionableYMAB, CRON, NAGE, and PRAX HeadlinesRecent News About These CompaniesOppenheimer Has Lowered Expectations for Y-mAbs Therapeutics (NASDAQ:YMAB) Stock PriceMay 31, 2025 | americanbankingnews.comY-mAbs Therapeutics (NASDAQ:YMAB) Price Target Lowered to $15.00 at OppenheimerMay 30, 2025 | marketbeat.comWedbush Reiterates Outperform Rating for Y-mAbs Therapeutics (NASDAQ:YMAB)May 29, 2025 | marketbeat.comWedbush Reaffirms "Outperform" Rating for Y-mAbs Therapeutics (NASDAQ:YMAB)May 29, 2025 | marketbeat.comY-mAbs Therapeutics (NASDAQ:YMAB) Given "Outperform" Rating at WedbushMay 29, 2025 | americanbankingnews.comY-mAbs Hosts Virtual Radiopharmaceutical R&D Update Highlighting Clinical Progress and Expanded PipelineMay 28, 2025 | globenewswire.comInfinitum Asset Management LLC Purchases New Stake in Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB)May 28, 2025 | marketbeat.comY-mAbs Therapeutics, Inc. (YMAB) Unveils Promising Cancer Trial Data at ANR 2025May 26, 2025 | insidermonkey.comY-mAbs Therapeutics Presents GD2-SADA Data at Advances in Neuroblastoma Research MeetingMay 26, 2025 | quiverquant.comY-mAbs Presents GD2-SADA PRIT Trial in Progress Poster at the Advances in Neuroblastoma Research MeetingMay 26, 2025 | globenewswire.comY-mAbs Therapeutics’ SWOT analysis: antibody innovator’s stock faces growth hurdlesMay 24, 2025 | investing.comHC Wainwright Brokers Decrease Earnings Estimates for YMABMay 23, 2025 | marketbeat.comFY2026 Earnings Forecast for YMAB Issued By HC WainwrightMay 22, 2025 | marketbeat.comY-mAbs Therapeutics (NASDAQ:YMAB) Price Target Cut to $11.00 by Analysts at HC WainwrightMay 21, 2025 | marketbeat.comD. E. Shaw & Co. Inc. Has $4.82 Million Stake in Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB)May 20, 2025 | marketbeat.comWedbush Cuts Earnings Estimates for Y-mAbs TherapeuticsMay 17, 2025 | marketbeat.comY-mAbs Therapeutics, Inc. (NASDAQ:YMAB) Receives Average Rating of "Moderate Buy" from BrokeragesMay 17, 2025 | marketbeat.comTruist Financial Sticks to Its Buy Rating for Y-Mabs Therapeutics (YMAB)May 16, 2025 | theglobeandmail.comParadigm Biocapital Advisors LP Grows Holdings in Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB)May 16, 2025 | marketbeat.comY-mAbs Therapeutics Inc (YMAB) Q1 2025 Earnings Call Highlights: Navigating Growth and ChallengesMay 14, 2025 | finance.yahoo.comY-mAbs Therapeutics, Inc.: Y-mAbs Reports First Quarter 2025 Financial Results and Recent Corporate DevelopmentsMay 13, 2025 | finanznachrichten.deNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesView All HeadlinesPalantir Scores First $1 Billion Contract; Is It Priced In?By Chris Markoch | May 27, 2025View Palantir Scores First $1 Billion Contract; Is It Priced In?These Are the Only 6 Stock Stocks in NVIDIA's 13F PortfolioBy Leo Miller | May 22, 2025View These Are the Only 6 Stock Stocks in NVIDIA's 13F PortfolioThese 4 Top Investors Bought Over 6 Million Broadcom Shares in Q1By Leo Miller | May 22, 2025View These 4 Top Investors Bought Over 6 Million Broadcom Shares in Q1Analysts Are Bullish on Marvell Stock Despite Amazon Deal ConcernBy Leo Miller | June 2, 2025View Analysts Are Bullish on Marvell Stock Despite Amazon Deal Concern3 Alternative Asset Managers Are Raising Dividends by 5% to 25%By Leo Miller | May 13, 2025View 3 Alternative Asset Managers Are Raising Dividends by 5% to 25%YMAB, CRON, NAGE, and PRAX Company DescriptionsCronos Group NASDAQ:CRON$1.96 +0.03 (+1.30%) As of 10:33 AM Eastern This is a fair market value price provided by Polygon.io. Learn more.Cronos Group Inc. operates as a cannabinoid company that engages in the cultivation, production and marketing of cannabis products in Canada, Israel, and Germany. It offers dried flower, pre-rolls, oils, vaporizers, edibles, and cannabis tinctures under the Spinach, Lord Jones, and PEACE NATURALS brands. Cronos Group Inc. was founded in 2012 and is based in Toronto, Canada.Niagen Bioscience NASDAQ:NAGE$11.90 +0.12 (+1.02%) As of 10:14 AM EasternNiagen Bioscience, Inc. is a global bioscience company, which engages in acquiring, developing, and commercializing proprietary-based ingredient technologies. It is pioneering research on nicotinamide adenine dinucleotide (NAD+). The company’s patent portfolio includes Nicotinamide Riboside (NR) and other NAD+ precursors, which are commercialized as the flagship ingredient Niagen. It operates through the following segments: Consumer Products, Ingredients, and Analytical Reference Standards and Services. The Consumer Products segment provides finished dietary supplement products that contain the firm’s proprietary ingredients directly to consumers as well as to distributors. The Ingredients segment supplies ingredients as raw materials to the manufacturers of consumer products. The Analytical Reference Standards and Services segment includes supply of phytochemical reference standards and other research and development services. The company was founded by Mark S. Germain and Frank L. Jaksch, Jr. in 1999 and is headquartered in Los Angeles, CA.Praxis Precision Medicines NASDAQ:PRAX$42.54 +1.35 (+3.26%) As of 10:33 AM Eastern This is a fair market value price provided by Polygon.io. Learn more.Praxis Precision Medicines, Inc., a clinical-stage biopharmaceutical company, engages in the development of therapies for central nervous system disorders characterized by neuronal excitation-inhibition imbalance. It is developing ulixacaltamide, a small molecule inhibitor of T-type calcium channels that is in Phase III clinical trial for the treatment of essential tremor; PRAX-562 for the treatment of pediatric patients with developmental and epileptic encephalopathies (DEE); and PRAX-628 to treat focal epilepsy. The company also develops PRAX-222 for the treatment of pediatric patients with early-onset SCN2A-DEE; PRAX-020 to treat KCNT1 related epilepsies; PRAX-080 for the treatment of PCDH19; and PRAX-090 and PRAX-100 for SYNGAP1 and SCN2A-LoF. It has a license agreement with RogCon Inc.; a research collaboration and license agreement with Ionis Pharmaceuticals, Inc.; a strategic collaboration and license agreement with UCB Biopharma SRL; and collaboration with The Florey Institute to develop three novel ASOs. The company was incorporated in 2015 and is based in Boston, Massachusetts.Y-mAbs Therapeutics NASDAQ:YMAB$5.06 +0.19 (+3.80%) As of 10:33 AM Eastern This is a fair market value price provided by Polygon.io. Learn more.Y-mAbs Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of antibody based therapeutic products for the treatment of cancer in the United States and internationally. It offers DANYELZA, a monoclonal antibody in combination with granulocyte-macrophage colony-stimulating factor for the treatment of pediatric patients with relapsed or refractory high-risk neuroblastoma in the bone or bone marrow. The company is also developing DANYELZA for the treatment of patients with second-line relapsed osteosarcoma and is in Phase II clinical study; GD2-SADA, which is in Phase I clinical trial for the treatment of GD2 positive solid tumor; and Omburtamab, a murine monoclonal antibody for the treatment of central nervous system/leptomeningeal metastases from neuroblastoma, as well as SADA PRIT technology platform. In addition, it is engages in the developing of CD38-SADA and GD2-GD3 Vaccine. The company has a license agreement with Memorial Sloan Kettering Cancer Center and Massachusetts Institute of Technology to develop and commercialize licensed products. Y-mAbs Therapeutics, Inc. was incorporated in 2015 and is headquartered in New York, New York. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas TSMC Joins NVIDIA in UAE Push, Fueling Growth Outlook Constellation Energy and Meta Strike Nuclear Deal, Shares Whipsaw Archer's Midnight Air Taxi Soars, But Stock Doesn’t Budge Microsoft Stock Near Peak, Pullback Seen as Opportunity 3 Reasons Amazon Could Be the Best Tech Performer in June 3 Tech Stocks Insiders Are Buying: Speculative Plays for June Tesla’s Lofty 200 P/E Could Mean More Upside Ollie’s Q1 Earnings: The Good, the Bad, and What’s Next Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
